Az új méhnyakszűrési irányelv megalkotásában két fontos szempont játszott szerepet. Az egyik az a bizonyított tény, hogy a méhnyakrák és rák előtti állapotok kialakulásában oki szerepet játszik a humán papillomavírus magas kockázatú törzsei okozta fertőzés. A másik a HPV-fertőzés biológiai viselkedésének beépítése az új szűrési eljárásba. Az új szűrési eljárásnak hűen tükröznie kell a méhnyak karcinogenezisét. A szervezett, populációszintű, életkor-specifikus méhnyakszűrés fokozná az átszűrtségi arányt, valamint a szűrés érzékenységének a fokozásával csökkenthetné az intervallumrákok számát. Orv Hetil. 2017; 158(52): 2062–2067.
Quinn M, Babb P, Jones J, et al. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318: 904–908.
Vajda R, Árváné Egri C, Kovács A, et al. Assessment of the pilot program for cervical cancer screening by health visitors. [A védőnői méhnyakszűrési pilot program értékelése.] Orv Hetil. 2017; 158: 461–467. [Hungarian]
Döbrőssy L, Koiss R. “Gynaecological cancer screening” or “cervical screening”? The case of Hungary. Eur J Gynaecol Oncol. 2016; 37: 445–450.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents: a review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012; 100B: 1–441.
Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008; 337: a1754.
Rebolj M, Bonde J, Njor SH, et al. Human papillomavirus testing in primary cervical screening and the cut-off level for hybrid capture 2 tests: systematic review. BMJ 2011; 342: d2757.
Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014; 18: dju153.
Wright TC, Stoler MH, Behrens CM, et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol. 2015; 136: 189–197.
Kjær SK, Frederiksen K, Munk C, et al. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. J Natl Cancer Inst. 2010; 102: 1478–1488.
Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013; 17(Suppl 1): S28–S35.
Petry KU, Cox JT, Johnson K, et al. Evaluating HPV-negative CIN2+ in the ATHENA trial. Int J Cancer 2016; 138: 2932–2939.
Rodríguez-Carunchio L, Soveral I, Steenbergen RD, et al. HPV-negative carcinoma of the uterine cervix: a distinct type of cervical cancer with poor prognosis. BJOG 2015; 122: 119–127.
Koiss R. Screening methods in prevention of cervical cancer. In: Vanden Broeck D. (ed.) Human papillomavirus and related diseases. From bench to bedside. InTech, Rijeka, 2012; pp. 65–76.
Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 156: 880–891.
Gök M, Heideman DA, van Kemenade FJ, et al. Offering self-sampling for human papillomavirus testing to non-attendees of the cervical screening programme: Characteristics of the responders. Eur J Cancer 2012; 48: 1799–1808.
De Kok IM, van Rosmalen J, Dillner J, et al. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model. BMJ 2012; 344: e670.
Lew JB, Simms K, Smith M, et al. Effectiveness modelling and economic evaluation of primary HPV screening for cervical cancer prevention in New Zealand. PLoS One 2016; 11: e0151619.
Simms KT, Hall M, Smith MA, et al. Optimal management strategies for primary HPV testing for cervical screening: cost-effectiveness evaluation for the National Cervical Screening Program in Australia. PLoS One 2017; 12: e0163509.